Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Champions Oncology (CSBR) Research & Development (2016 - 2026)

Champions Oncology has reported Research & Development over the past 17 years, most recently at $2.3 million for Q1 2026.

  • For Q1 2026, Research & Development rose 32.11% year-over-year to $2.3 million; the TTM value through Jan 2026 reached $8.9 million, up 29.22%, while the annual FY2025 figure was $6.8 million, 28.49% down from the prior year.
  • Research & Development for Q1 2026 was $2.3 million at Champions Oncology, down from $2.6 million in the prior quarter.
  • Over five years, Research & Development peaked at $3.2 million in Q1 2023 and troughed at $1.5 million in Q3 2024.
  • A 5-year average of $2.3 million and a median of $2.3 million in 2026 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: tumbled 47.94% in 2024 and later soared 54.88% in 2025.
  • Year by year, Research & Development stood at $2.6 million in 2022, then decreased by 3.42% to $2.5 million in 2023, then crashed by 32.84% to $1.7 million in 2024, then soared by 54.88% to $2.6 million in 2025, then dropped by 13.19% to $2.3 million in 2026.
  • Business Quant data shows Research & Development for CSBR at $2.3 million in Q1 2026, $2.6 million in Q4 2025, and $2.1 million in Q3 2025.